Full Text
PCN86 Cost-Utility Analysis of Nilotinib Compared to Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase

Abstract

Authors

T.J. Inocencio A. Seetasith A. Newland P. Bose D. Holdford

Back to Volume 15, Issue 4
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×